

Date	Topic	AEST	GMT
Thursday 2 April			10.00 a.m. – 11.30 a.m.
Thursday 9 April	An analysis of COVID-19 risk treatments and controls	8.00 p.m. – 9.30 p.m.	11.00 a.m. – 12.30 p.m.
Thursday 16 April	A practical approach for processes to manage COVID-19 risks (including decision making)	8.00 p.m. – 9.30 p.m.	11.00 a.m. – 12.30 p.m.
Thursday 23 April	Effective COVID-19 risk governance, reporting and communication	8.00 p.m. – 9.30 p.m.	11.00 a.m. – 12.30 p.m.
Thursday 30 April	Participant preferences and feedback	8.00 p.m. – 9.30 p.m.	11.00 a.m. – 12.30 p.m.





Your Presenters



Manoj Kulwal Co-Founder & CRO at RiskSpotlight





David Tattam Director, Research and Training The Protecht Group





Jason Smith CEO and Executive Director at Risk Management Institute of Australasia



3

Agenda

- Introduction and Housekeeping
- Presentation 1 COVID-19 Risk Treatments and Controls **Analysis**
- Presentation 2 COVID-19 Treatments and Controls in **Practice**
- Q&A
- Conclusions and next Webinar





Housekeeping

1. The webinar will go for 90 minutes.

 Introduction 10 mins Presentation 1 20 mins 20 mins Presentation 2 Q&A 35 mins Concluding Remarks 5 mins

- 2. Ask questions as we go. Enter your question in the question section on the GOTO control panel. If the question input area is not visible, click on the orange arrow at the top of the panel to expand the viewing area.
- 3. Any questions we don't get to during the webinar:
 - · We will address any key questions at the beginning of the next Webinar
 - · We will consider writing a blog or including a topic for any questions that are themed
- 4. A recording of this webinar will be made available to registered participants as well on our websites:
 - · www.protechtgroup.com
 - www.riskspotlight.com



5

Agenda

- Introduction and Housekeeping
- Presentation 1 COVID-19 Risk Treatments and Controls **Analysis**
- Presentation 2 COVID-19 Treatments and Controls in **Practice**
- Q&A
- Conclusions and next Webinar



1. Stakeholders - Communicate and






8. Governance, Reporting and Communications

7. Processes to Monitor, Review, Record and

Consult



- 2. Scope and Context 2.1 Where are we now? 2.2 Where do we want to be? 2.3 Critical Steps
- 3,4,5. Identifying, Analysing and **Evaluating the Risks**
- 6. Risk Treatment and Controls



Manage



Source: ISO 31000:2018 Risk Management: Principles and guidelines

7

Risk Treatments and Controls

- 1. What are the **Risks** to treat and control
- 2. Risk Treatment methods and control types and application to COVID-19 infection risk
- 3. **Deciding on which treatment method** balancing cost and benefit
- 4. **Assurance and reporting** on the control environment









1. Risks to Treat and Control

- 1. Existing risks have changed
 - Increased level of inherent risk (Cyber, data security, WHS etc.)
 - Increased level of residual risk because of reduced level of control from staff relocations and high % of manual controls
- 2. New risks e.g.
 - COVID-19 infection risk
 - Non-essential service risk (e.g. solicitors to effect conveyancing)





Polling Question


How well has your Pandemic / Business Continuity Plan worked in managing the COVID-19 crisis to date?

- A. Not at all
- B. Not very well
- C. OK
- D. Well
- E. Very well











11









Treatment method	Description	Examples for COVID-19
1.Accept the risk	When the risk is within appetite and at the risk's targeted / desired level	All risks where we are comfortable with the current level.
2.Process re-engineer / transform the risk	Process re-engineering to de-risk the process.	Working from home. This has changed the nature of risks we face, reducing the infection risk but potentially increasing other risks such as Cyber.
3.Improve controls	Aimed at strengthening controls in order to reduce the risk further. This covers Preventive, Detective and Reactive / Corrective controls.	Examples later.
4.Transfer the impact	Transferring some or all of the financial impact of a risk to another party. Main methods are insurance and risk sharing service level agreements. It is only useful for reducing the financial impact.	This is a special type of reactive control which is aimed at reducing impairs a special type of reactive control which is aimed at reducing impairs.
5.Accept the risk outside o appetite	Formal acceptance of the risk when it is outside of appetite. Requires delegated authority sign-off and a finite period for which the acceptance is given.	
		Practiced by many medical staff who accept high levels of infection risk order to help others.
6.Avoid	This involves stopping the activity that causes the risk.	Total isolation from people, products and services that could cause infection.
7.Reduce controls	This involves decreasing the controls based on cost / benefit.	This may occur when the control is too costly / stops the person achieving their objectives adequately.
		Medical staff who deliberately remove social distancing in order to help patient.





Controls ISO 31000:2018

"Measure that maintains and / or modifies risk"

Key risk characteristics are:

- Likelihood of the risk occurring
- Consequence if the risk were to occur

Protecht


"A specific action taken with the objective of reducing either the likelihood of the risk occurring, and / or the impact if the risk were to occur. "







15




16


Copyright: The Protecht Group. These materials must not be copied, translated into any other media or distributed to any other person without the express permission of The Protecht Group. All IP contained within these materials remains the property of The Protecht Group.







17








Type of control	Examples	
Preventive	Based on preventing getting infected • Social distancing / Isolation • Hand-washing • Surface cleaning • Gloves • Masks (although of limited benefit we understand)	
Detective	 Monitoring if contact made with infected person / high risk person Body temperature monitoring with thermometers Infection testing 	
Reactive / Corrective / Responsive	Based on you not infecting someone else Isolation Hand-washing Surface cleaning Gloves Face mask Based on managing personal impacts Medical attention Income protection / Health / Life insurance	


19



20

Copyright: The Protecht Group. These materials must not be copied, translated into any other media or distributed to any other person without the express permission of The Protecht Group. All IP contained within these materials remains the property of The Protecht Group.





The "Cost" of Control

- 1. \$ Financial
- 2. Time staff and management
- 3. Direct impact on objectives (positive and negative)
- 4. Additional risk and cost of managing that risk









Polling Question

To what degree has your organisation analysed the costs and benefits of each treatment method for COVID-19 related risk(s)?

- A. No formal analysis conducted it is based on gut feel and what everyone else is doing?
- B. Some analysis carried out
- C. Full analysis completed for each treatment decision







23


4. Assurance and Reporting on the Controls Environment


- 1. Can Line 1 continue effective controls assurance, especially over manual controls?
- 2. Do control assurance tests need to be modified as controls have changed?
- 3. How can Line 2 effectively review and challenge Line 1?
- 4. How can Line 3 effectively audit Lines 2 and 1?











26

Copyright: The Protecht Group. These materials must not be copied, translated into any other media or distributed to any other person without the express permission of The Protecht Group. All IP contained within these materials remains the property of The Protecht Group.





Polling Question

Has your organisation set up a specific COVID-19 Crisis Management Team?

- A. Yes
- B. No







27

Agenda

- Introduction and Housekeeping
- Presentation 1 COVID-19 Risk Treatments and Controls **Analysis**
- Presentation 2 COVID-19 Treatments and Controls in **Practice**
- Q&A
- Conclusions and next Webinar








RiskSpotlight Portal: COVID-19 OpRisks & Treatments - 2 months for free at www.riskspotlight.com/portaltrial tlight Portal Home Page COVID-19 News COVID-19 Risks and Treatments OpRisk Analysis OpRisk Radar












31


















RiskSpotlight Portal: COVID-19 OpRisks & Treatments - 2 months for free at www.riskspotlight.com/portaltrial RiskSpotlight Portal Home Page | COVID-19 News | COVID-19 Risks and Treatments | OpRisk Analysis | OpRisk Radar 96659 HS1. Illness or death of employees due to COVID-19 infection in the work environment the work environment Practices 1 24 30 CG Apr. Practices 1 2725 Review the business strategy and make changes to align with the new realities emerging from the crisis Strategy. PC2, Disruption to customer related business processes due to third parties being unable to fulfil their obligations

1. Critical Business Process Execution Failures PROTECHT RiskSpotlight





Polling Question

Which of the following best reflects your organisation's control environment in response to the COVID-19 crisis?

- A. Strong. We have not implemented any new controls
- B. Sufficient but we had to implement some additional controls
- C. Weak. Many new / changed controls required








37

Agenda

- Introduction and Housekeeping
- Presentation 1 COVID-19 Risk Treatments and Controls **Analysis**
- Presentation 2 COVID-19 Treatments and Controls in **Practice**
- Q&A
- Conclusions and next Webinar







Agenda

- Introduction and Housekeeping
- Presentation 1 COVID-19 Risk Treatments and Controls **Analysis**
- Presentation 2 COVID-19 Treatments and Controls in **Practice**
- Q&A
- Conclusions and next Webinar









Manoj Kulwal Co-Founder & CRO at RiskSpotlight





David Tattam Director, Research and Training

The Protecht Group





Jason Smith


CEO and Executive Director at Risk Management Institute of Australasia



41

41

What's Next?



Next Week's Topic

A practical approach for processes to manage COVID-19 risks

Thu 16 April 10-11.30am BST 8-9.30pm AEST



Compliance Webinar Risk in a Covid-19

Leveraging your **ERM** Framework to painlessly manage Regulatory and **Ethical Compliance**

Tue 21 April 10-10.40am BST 12-12:40pm AEST



World

Key insights on risk and compliance in a Covid-19 world

protechtgroup.com/covid-19



Managing COVID-19 OpRisks

COVID-19 Resources from RiskSpotlight

riskspotlight.com/covid19





